COS.L

Collagen Solutions Plc
Collagen Sol PLC - Director/PDMR Shareholding
28th August 2020, 14:27
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5084X
Collagen Solutions PLC
28 August 2020
 

Collagen Solutions plc

(the "Company")

 

Director/PDMR Dealing

 

1.    Vesting / exercise of Deferred Bonus Awards granted in October 2019

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that, on 28 August 2020, the executive director and other persons discharging managerial responsibility ("PDMRs") set out in the table below acquired ordinary shares of 1 pence each in the share capital of the Company ("Shares") pursuant to the vesting / exercise of awards originally granted under the Collagen Solutions plc Deferred Bonus Plan on 2 October 2019 (the "Awards").  No consideration was payable for these Shares.

 

Director/PDMR

Position

Number of Shares acquired on 28 August 2020

Jamal Rushdy

Chief Executive Officer

906,145

Lou Ruggiero

Chief Business Officer

806,559

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

Chris Wattengel

PDMR / VP Global R&D

246,514

Kevin Darling

PDMR / VP Tissue Products

173,596

 

Notes:

1               A number of other individuals, including Hilary Spence, Chief Financial Officer, were also granted Awards under the Deferred Bonus Plan on 2 October 2019.  Although these Awards (which are in the form of "nil-cost" options) have now vested, the relevant holders have not yet elected to exercise their rights and acquire their Shares.

 

The Shares required to satisfy the above vestings / exercises were transferred to the relevant individuals by the trustee of the Collagen Solutions plc Employee Benefit Trust (the "EBT"). As previously announced, these Shares were allotted to the EBT on 11 August 2020.

 

2.    Total beneficial holdings in the Company

 

Following the above notifications, the total holdings of Shares of the relevant PDMRs are as follows:

 

Director/PDMR

Position

Total holding following this notification

Approximate % of the Company's issued share capital

Jamal Rushdy

Chief Executive Officer

1,906,145

0.43%

Lou Ruggiero

Chief Business Officer

806,559

0.18%

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

0.06%

Chris Wattengel

PDMR / VP Global R&D

246,514

0.06%

Kevin Darling

PDMR / VP Tissue Products

173,596

0.04%

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1.    Jamal Rushdy

2.    Lou Ruggiero

3.    Brad Selman

4.    Chris Wattengel

5.    Kevin Darling

2

Reason for the notification

a)

Position/status

1.    Chief Executive Officer

2.    Chief Business Officer

3.    PDMR / VP Global Sales and Marketing

4.    PDMR / VP Global R&D

5.    PDMR / VP Tissue Products

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Collagen Solutions plc

b)

LEI

213800IFY1CVGRGETL95

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 1p each ("Shares")

Identification code

ISIN Code: GB00B94T6Y14

b)

Nature of the transaction

Acquisition of Shares on the vesting / exercise of Awards originally granted on 2 October 2019 pursuant to the Collagen Solutions plc Deferred Bonus Plan

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

1.

nil

906,145

2.

nil

806,559

3.

nil

284,202

4.

nil

246,514

5.

nil

173,596

d)

Aggregated information

-   Aggregated volume

-   Price

1.    N/A single transaction

2.    N/A single transaction

3.    N/A single transaction

4.    N/A single transaction

5.    N/A single transaction

e)

Date of the transaction

2020-08-28

f)

Place of the transaction

Outside a trading venue

 

Enquiries:

Collagen Solutions Plc


Jamal Rushdy, CEO

 

Hilary Spence, CFO

Via Walbrook



Cenkos Securities Plc (Nominated Adviser and Broker)


Giles Balleny (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys




Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com   

Anna Dunphy

Mob: 07876 741 001

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKFBBQBKDPFB ]]>
TwitterFacebookLinkedIn